Pharma Focus Asia

Innovent Biologics and Synaffix Broaden ADC Collaboration After Positive Initial Clinical Signals From Ongoing Phase 1 Study

Friday, December 08, 2023

Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality medicines for various medical conditions, has recently expanded its licensing agreement with Synaffix B.V., a Lonza company (SIX:LONN) focused on advancing its clinical-stage platform technology for antibody-drug conjugates (ADCs) with an exceptional therapeutic index.

This expanded collaboration follows a previous partnership established in June 2021, where Innovent was granted rights to use Synaffix's ADC technologies, including GlycoConnect®, HydraSpace®, and one of its toxSYN® linker-payloads, on a target-specific, non-exclusive basis. The initial agreement revolved around a therapeutic molecule (Innovent R&D code: IBI343, a CLDN18.2 ADC) that has progressed to Phase 1 clinical development.

Under the updated terms of the agreement, Innovent will focus on developing at least one new ADC candidate, utilizing Synaffix's ADC technology to achieve optimal efficacy and tolerability. Innovent will be responsible for the entire lifecycle of these new ADC candidates, covering research, development, manufacturing, and commercialization. Synaffix is set to receive an upfront payment along with potential milestone payments and royalties on commercial sales for each licensed target.

Dr. Kaijie He, Vice President of Cancer Biology and ADC Research at Innovent, stated, "Innovent has advanced one ADC candidate through the initial phase of our collaboration with Synaffix to the clinical development stage. This expanded deal introduces additional novel ADCs to our research projects, allowing us to deepen our understanding of ADC research and expand our ADC pipeline."

Peter van de Sande, Head of Synaffix, commented, "Innovent, with its focus on innovative medicines and R&D expertise, has proven to be an ideal partner for us. Our partnership has gained momentum with IBI343, and we look forward to broadening our collaboration by leveraging our technology platform, which includes enabling the off-the-shelf conversion of antibodies into ADCs. Paired with Innovent's world-leading clinical development capabilities and its strong track record, we anticipate swift advancement of product candidates to the clinic."

IBI343 is a recombinant human anti-Claudin 18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. This ADC binds to Claudin 18.2-expressing tumor cells, leading to internalization of the ADC and subsequent release of the drug, causing DNA damage and ultimately apoptosis of the tumor cells. Additionally, the liberated drug can diffuse across the plasma membrane, inducing a "bystander killing effect" on neighboring cells. Currently, a Phase I study of IBI343 is underway in Australia and China (NCT05458219) to evaluate its safety, tolerability, and preliminary efficacy in subjects with advanced solid tumors.

 

Source: prnasia.com

magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024